USA flag logo/image

An Official Website of the United States Government

Designed Antimalarial Agents Overcoming Chloroquine-Resistance

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85300
Program Year/Program:
2007 / STTR
Agency Tracking Number:
AI072923
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
DESIGNMEDIX, INC.
2828 Corbett Ave Suite 140A PORTLAND, OR 97201-4830
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: Designed Antimalarial Agents Overcoming Chloroquine-Resistance
Agency: HHS
Contract: 1R41AI072923-01
Award Amount: $103,876.00
 

Abstract:

DESCRIPTION (provided by applicant): The intent of the work presented in this proposal is to counter the worldwide health problem brought on by the spread of chloroquine-resistant malaria. To address the need for an orally available and inexpensive replace ment drug, we have developed a novel class of molecules called reversed chloroquines (RCQs) which act against both chloroquine-resistant and chloroquine-sensitive malaria. Herein we describe a new sub-class of RCQ molecules, which we term branched RCQ (b RCQ) molecules. These bRCQ molecules may be even better than the 'simple' RCQs. The goal of the described project is to understand how to optimize structural features in the bRCQ molecules to yield the best possible, orally available drug against malaria. This will be accomplished by producing a panel of varied bRCQ structures, and then testing them against chloroquine-sensitive and chloroquine-resistant malaria in red cell culture (an in vitro test), as well as for solubility, central nervous system recept or activity, and cytotoxicity. The most promising candidates will then be evaluated as orally available drugs against malaria in mice. Once these experiments demonstrate the feasibility of the bRCQ molecular design, as well as provide fundamental understan ding of correlations between molecular features and efficacy of bRCQs against malaria, the bRCQ structures will be tuned in order to optimize practical aspects of their use in humans. Although we are directing this study specifically against P. falciparu m, the most problematic human malaria variant, bRCQs should also be effective against the other human malarias. Although there may be a very thin profit margin to be had some 'endemic markets', there is an increasing ability to pay for drugs in countries s uch as India and China and the military and traveler markets have promise for reasonable commercialization.

Principal Investigator:

David H. Peyton
5037253875
PEYTOND@PDX.EDU

Business Contact:


sandysh@pacifier.com
Small Business Information at Submission:

DESIGNMEDIX, LLC
DESIGNMEDIX, LLC 7505 SE 36TH AVE PORTLAND, OR 97202

EIN/Tax ID: 126277928
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
PORTLAND STATE UNIVERSITY
PORTLAND STATE UNIVERSITY
BOX 751
PORTLAND, OR 97207 3098
RI Type: Nonprofit college or university